About: GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.43 (-7.14%)
GRI NASDAQ GRI Bio Inc.
GRI Bio Inc. share price
GRI price activity
Last Price
$1.430
Change (24hr)
-0.11 USD (7.14%)
Volume
48.38K
Volume (4w avg)
-
Open
$1.53
Day Range
$1.36 - $1.54
Previous Close
$1.54
Last Trade
04 Nov, 9:00 pm GMT+0
Delayed
04 Nov, 9:00 pm GMT+0
GRI price performance
Delayed
04 Nov, 9:00 pm GMT+0
GRI details
GRI Market Signals